Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.
Alzheimer's & dementia (New York, N. Y.)（2022）
摘要
Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
更多查看译文
关键词
dementia,glucagon‐like peptide‐1 receptor agonists,randomized controlled trial,real‐world evidence,type 2 diabetes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要